164 related articles for article (PubMed ID: 27792106)
1. Giant Cell Tumor of Cervical Spine Presenting as Acute Asphyxia: Successful Surgical Resection After Down-Staging With Denosumab.
Kumar R; Meis JM; Amini B; McEnery KW; Madewell JE; Rhines LD; Benjamin RS
Spine (Phila Pa 1976); 2017 May; 42(10):E629-E632. PubMed ID: 27792106
[TBL] [Abstract][Full Text] [Related]
2. The risk of neurological deterioration while using neoadjuvant denosumab on patients with giant cell tumor of the spine presenting with epidural disease: a meta-analysis of the literature.
Al Farii H; McChesney G; Patel SS; Rhines LD; Lewis VO; Bird JE
Spine J; 2024 Jun; 24(6):1056-1064. PubMed ID: 38301904
[TBL] [Abstract][Full Text] [Related]
3. Risks and benefits of combining denosumab and surgery in giant cell tumor of bone-a case series.
Müller DA; Beltrami G; Scoccianti G; Campanacci DA; Franchi A; Capanna R
World J Surg Oncol; 2016 Nov; 14(1):281. PubMed ID: 27809843
[TBL] [Abstract][Full Text] [Related]
4. Giant cell tumor of the cervical spine: a series of 22 cases and outcomes.
Junming M; Cheng Y; Dong C; Jianru X; Xinghai Y; Quan H; Wei Z; Mesong Y; Dapeng F; Wen Y; Bin N; Lianshun J; Huimin L
Spine (Phila Pa 1976); 2008 Feb; 33(3):280-8. PubMed ID: 18303460
[TBL] [Abstract][Full Text] [Related]
5. Sustained long-term complete regression of a giant cell tumor of the spine after treatment with denosumab.
Mattei TA; Ramos E; Rehman AA; Shaw A; Patel SR; Mendel E
Spine J; 2014 Jul; 14(7):e15-21. PubMed ID: 24534393
[TBL] [Abstract][Full Text] [Related]
6. Short-term Preoperative Denosumab With Surgery in Unresectable or Recurrent Giant Cell Tumor of Bone.
Zhang RZ; Ma TX; Qi DW; Zhao M; Hu T; Zhang GC
Orthop Surg; 2019 Dec; 11(6):1101-1108. PubMed ID: 31762217
[TBL] [Abstract][Full Text] [Related]
7. Denosumab salvage therapy in an 11-year-old boy with locally recurrent unresectable giant cell tumor of the lumbar spine after surgery.
Luo Y; Xiu P; Chen H; Zeng J; Song Y; Li T
Neurochirurgie; 2023 May; 69(3):101427. PubMed ID: 36828057
[TBL] [Abstract][Full Text] [Related]
8. Does Denosumab Change the Giant Cell Tumor Treatment Strategy? Lessons Learned From Early Experience.
Agarwal MG; Gundavda MK; Gupta R; Reddy R
Clin Orthop Relat Res; 2018 Sep; 476(9):1773-1782. PubMed ID: 30794215
[TBL] [Abstract][Full Text] [Related]
9. Role of (Neo)adjuvant Denosumab for Giant Cell Tumor of Bone.
Palmerini E; Staals EL; Jones LB; Donati DM; Longhi A; Randall RL
Curr Treat Options Oncol; 2020 Jul; 21(8):68. PubMed ID: 32623530
[TBL] [Abstract][Full Text] [Related]
10. Denosumab treatment for progressive skull base giant cell tumor of bone in a 14 year old female - a case report and literature review.
Bardakhchyan S; Kager L; Danielyan S; Avagyan A; Karamyan N; Vardevanyan H; Mkhitaryan S; Papyan R; Zohrabyan D; Safaryan L; Sargsyan L; Harutyunyan L; Hakobyan L; Iskanyan S; Tamamyan G
Ital J Pediatr; 2017 Mar; 43(1):32. PubMed ID: 28356124
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors for local recurrence in extremity-located giant cell tumours of bone with pathological fracture.
Medellin MR; Fujiwara T; Tillman RM; Jeys LM; Gregory J; Stevenson JD; Parry M; Abudu A
Bone Joint J; 2018 Dec; 100-B(12):1626-1632. PubMed ID: 30499317
[TBL] [Abstract][Full Text] [Related]
12. Denosumab-treated Giant Cell Tumor of Bone Exhibits Morphologic Overlap With Malignant Giant Cell Tumor of Bone.
Wojcik J; Rosenberg AE; Bredella MA; Choy E; Hornicek FJ; Nielsen GP; Deshpande V
Am J Surg Pathol; 2016 Jan; 40(1):72-80. PubMed ID: 26414220
[TBL] [Abstract][Full Text] [Related]
13. Retrospective cohort study of 68 sacral giant cell tumours treated with nerve-sparing surgery and evaluation on therapeutic benefits of denosumab therapy.
Lim CY; Liu X; He F; Liang H; Yang Y; Ji T; Yang R; Guo W
Bone Joint J; 2020 Feb; 102-B(2):177-185. PubMed ID: 32009426
[TBL] [Abstract][Full Text] [Related]
14. Pre-operative denosumab is associated with higher risk of local recurrence in giant cell tumor of bone: a systematic review and meta-analysis.
Chen X; Li H; Zhu S; Wang Y; Qian W
BMC Musculoskelet Disord; 2020 Apr; 21(1):256. PubMed ID: 32312263
[TBL] [Abstract][Full Text] [Related]
15. Denosumab May Increase the Risk of Local Recurrence in Patients with Giant-Cell Tumor of Bone Treated with Curettage.
Errani C; Tsukamoto S; Leone G; Righi A; Akahane M; Tanaka Y; Donati DM
J Bone Joint Surg Am; 2018 Mar; 100(6):496-504. PubMed ID: 29557866
[TBL] [Abstract][Full Text] [Related]
16. Can Denosumab cure giant cell tumors of the spine? A case report and literature review.
Xará-Leite F; Coutinho L; Fleming C; Magalhães M; Oliveira V; Rodrigues-Pinto R; Cardoso P
Eur J Orthop Surg Traumatol; 2020 Jan; 30(1):19-23. PubMed ID: 31529151
[TBL] [Abstract][Full Text] [Related]
17. Denosumab in the treatment of giant cell tumor of the spine. Preliminary report, review of the literature and protocol proposal.
Boriani S; Cecchinato R; Cuzzocrea F; Bandiera S; Gambarotti M; Gasbarrini A
Eur Spine J; 2020 Feb; 29(2):257-271. PubMed ID: 31098716
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcome of recurrent giant cell tumor of the extremity in the era before molecular target therapy: the Japanese Musculoskeletal Oncology Group study.
Takeuchi A; Tsuchiya H; Ishii T; Nishida Y; Abe S; Matsumine A; Kawai A; Yoshimura K; Ueda T
BMC Musculoskelet Disord; 2016 Jul; 17():306. PubMed ID: 27448567
[TBL] [Abstract][Full Text] [Related]
19. Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone.
Rutkowski P; Ferrari S; Grimer RJ; Stalley PD; Dijkstra SP; Pienkowski A; Vaz G; Wunder JS; Seeger LL; Feng A; Roberts ZJ; Bach BA
Ann Surg Oncol; 2015 Sep; 22(9):2860-8. PubMed ID: 26033180
[TBL] [Abstract][Full Text] [Related]
20. Pseudomyogenic hemangioendothelioma of bone treated with denosumab: a case report.
Otani S; Nakayama R; Sekita T; Hirozane T; Asano N; Nishimoto K; Sasaki A; Okita H; Morioka H; Nakamura M; Matsumoto M
BMC Cancer; 2019 Sep; 19(1):872. PubMed ID: 31481040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
